



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/780,661	02/19/2004	Syed Rizvi	976	2178
67911 HPF P.O. BOX 4442 CHESTERFIELD, MO 63006-4442	7550 12/02/2009		EXAMINER GHALL, ISIS A D	
			ART UNIT 1611	PAPER NUMBER
			MAIL DATE 12/02/2009	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/780,661

Applicant(s)

RIZVI, SYED

Examiner

Isis A. Ghali

Art Unit

1611

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 August 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-10 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-10 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SF/ICE)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

The receipt is acknowledged of applicant's amendment filed 08/03/2009.

Claims 1-10 are pending and included in the prosecution.

The following rejections have been overcome by virtue of applicant's amendment and remarks:

The rejection of claims 1-10 under 35 U.S.C. 112, second paragraph as being indefinite.

The rejection of claims 4 and 7 under 35 U.S.C. 103(a) as being unpatentable over Garg et al., or over the combination of Garg et al. and US '690, and further in view of the article "Natural Deodorant" by Carrubba Inc.

The following new ground of rejection is necessitated by applicant's amendment:

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 4 and 7 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter

which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 4 and 7 as amended recite "liquid composition consists of 4-6 percent by volume *saccharomyces ferment*, 0.4-0.6 percent by volume poly(oxy-1,2-ethanediyl), alpha-(4- (1,1,3,3 tetramethylbutyl)phenyl)-omega-hydroxy-, 0.15-0.25 percent by volume potassium sorbate, 0.15-0.25 percent by volume cetylpyridinium chloride, 0.04-0.06 percent by volume disodium EDTA; 0.04-0.06 percent by volume lactic acid, and 92- 95 percent by volume of water". The claims are picture claims that are limited to the recited elements and quantities, as applicant admits. The claims reflect the example disclosed in the present specification at page 6. The example recites the species as claimed by claims 4 and 7. However, claims 4 and 7 recite 0.04-0.06 percent by volume disodium EDTA and the example in page 6 contains "0.1% by volume" of disodium EDTA, which is much higher than the claimed range. Therefore, the subject matter of claims 4 and 7 as instantly claimed is not described in the original specification.

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 1-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1, 4, 5, and 7 as amended are indefinite because the claims recite the closed language "consisting of", however, the amounts of

the ingredients when added all together form 99.22% to 99.78% by volume of the composition. In view of the "consisting" language of the claims, elements are missing that forms from 0.78 to 0.225 by volume of the composition.

The following rejection has been discussed in details in the previous office action, and is maintained for reasons of record:

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 1-3, 5, 6, 8-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over the article "Compendium of Pharmaceutical Excipients for Vaginal Formulations" by Garg et al. by itself or combined with US 2002/0142690 ('690).

Garg et al. teach ideal vaginal formulation with desired characteristics in terms of safety, efficacy, patient compliance, aesthetic, acceptability to regulatory authorities, and cost requirements (page 14). Garg et al. teach towel to clean external vaginal area comprising lactic acid, water, potassium sorbate, O-9 (octoxynol-9), EDTA, cetylpyridinium chloride, and fragrance (page 17). Garg et al. further teach absorbent cotton in tampons as a carrier (top of page 18), and absorbent cotton tampon implies that it absorbs the composition applied to it to form impregnated substrate. Garg et al.

teach amount of lactic acid is between 0.015 -6.6 %; amount of potassium sorbate is between 0.1-0.2%; amount of emulsifier can be as low as 0.3% for polyoxyethylene-polyoxypropylene copolymer, 0.5% for sodium lauryl sulfate, or 0.3-0.55 for cholesterol; amount of EDTA is between 0.01-0.1%; amount of preservative is between 0.01-0.02% (pages 18-22). Garg et al. teach alum potassium in the composition (page 18), claimed by applicant as odor absorbing agent.

Although Garg et al. teach all the ingredients of the product as instantly claimed, however, the reference does not explicitly teach the amount of the odor absorbing agent, or amount of antiseptic cetylpyridinium.

Garg et al. suggest the generic teaching of the amount of preservatives as low as 0.1-0.2% for benzoic acid that is known as antiseptic agent.

Although Garg et al. do not specifically teach the amounts of some ingredients as claimed by applicant, however, the amount of a specific ingredient in a composition is clearly a result effective parameter that a person of ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for an artisan of ordinary skill to determine the optimal amount of each ingredient to add in order to best achieve the desired results. Thus, absent some demonstration of unexpected results from the claimed parameters, this optimization of ingredient amount would have been obvious at the time of applicant's invention.

Therefore, it would have been obvious to one having ordinary skill in the art at the time of the invention to provide towel or tampon impregnated with the composition

disclosed by Garg et al., and optimize the amounts of different ingredients in order to achieve the desired anti-infective effect and mean while maintaining pleasant odor of the composition.

Although Garg et al. implies the composition is absorbed into a substrate, however, Garg et al. does not explicitly teach the impregnation of the composition in the absorbent article.

US '690 teaches substrate of web fabric impregnated with composition comprising octooxynol-9, and deliver impregnated material upon wiping the contaminated surface, and avoid re-positioning the contaminant upon the surface which is being cleaned (abstract; paragraphs: 0023, 0025, 0029, 0031). The wipes can be handled safely, non-toxic, and even if misplaced poses little or no risk to the end user, and far more effective at removing stubborn embarrassing contaminants helping preventing sexually transmitted diseases (paragraph 0034).

Therefore, it would have been obvious to one having ordinary skill in the art at the time of the invention to provide towel or tampon comprising the composition disclosed by Garg et al., and optimize the amounts of different ingredients to obtain specific desired effect such as anti-infective effect, and further apply the composition to the towel or tampon by impregnation as disclosed by US '690. One would have been motivated to do so because Us '690 teaches that wipes impregnated with anti-infective composition can be handled safely, and even if misplaced poses little or no risk to the end user, and far more effective at removing stubborn embarrassing contaminants helping preventing sexually transmitted diseases. One would have reasonably expected

treating vaginal contamination safely and effectively with reduction of the risk of transmitting sexually transmitted diseases using substrate impregnated with the composition disclosed by Garg et al.

Response to Arguments

7. Applicant's arguments filed 08/03/2009 have been fully considered but they are not persuasive.

Applicant argues that the present claims exclude the presence of any fragrance while Garg et al. require fragrance. The declaration filed on March 26, 2008 under 37 C.F.R. § 132 demonstrated the significant and unexpected ability of the claimed devices and methods to control odor without the use of a fragrance. In view of the further use of the "consisting of" transitional phrase, the Claims unequivocally exclude the use of any fragrance. The towel disclosed by Garg uses fragrance. The deleted component by applicant's invention is a necessary component of the prior art, while maintaining its function. The present invention is capable of controlling odor without fragrance.

In response to this argument, it is argued that although claims 1 and 5 utilize the language "consist of", however, the ingredients recited by the claims do not form 100% of the composition, therefore permitting the presence of other ingredients such as fragrance disclosed by Garg et al. It has been held that omission of an element and its function is obvious if the function of the element is not desired. *Ex parte Wu*, 10 USPQ 2031 (Bd. Pat. App. & Inter. 1989). See also *In re Larson*, 340 F.2d 965, 144 USPQ 347 (CCPA 1965); and *In re Kuhle*, 526 F.2d 553, 188 USPQ 7 (CCPA 1975). The cited

prior art disclosed the claimed odor controlling agent, and showed some embodiments without fragrance. The prior art in combination teaches the present invention as a whole, and teach all the ingredients as instantly claimed, and same ingredients expected to have the same properties, such as odor control, since materials and their properties are inseparable. Odor control can be achieved by removing the cause of such odor. For example, to remove the bad odor of perspiration, antiperspirant agent can be used, and not necessary fragrance is used. The same apply here, the bad odor caused by vaginitis can be simply removed by treating vaginitis, without necessarily adding fragrance.

Regarding the declaration filed March 26, 2008, the present claims are directed to product and method of its use to treat vaginitis, and the declaration is directed to reduction of odor without the use of fragrance. The declaration showed that the claimed product controlled odor, and does not provide side by side comparison of fragrance with odor controlling agents in order to show the superior unexpected results.

Further, applicant's attention is directed to the scope of the present claims: claim 1 is product and claim 5 is method of treating vaginitis comprising one step of applying the claimed composition. All the elements of the product are disclosed by the Grag et al. by itself or combined with US '690. The claimed method requires one step of applying the composition to the affected body area, and Grag et al. disclosed that step. Grag et al. in page 15, at the bottom of the left column, stated that "Vaginal administration of drugs is mainly used for the treatment of local infections such as vaginitis, bacterial vaginosis, candidiasis and other infection". Further, Grag et al. in page 15, at the top of

the right column, stated that: "Vaginally administered agents and formulations are mainly used and are being developed to provide protection against microbial infections." Therefore, treatment of vaginitis is the main goal of Grag's reference, and further disclosed many formulations to achieve such a goal. The composition used as cleansing for the skin is expected to have anti-infective effect to treat vaginitis because Grag et al. in page 15, right column, teaches that the ingredients normally used as excipients possess potent antimicrobial activities, and further listed surfactants as example. Therefore, the ingredients used to cleanse the skin as disclosed by Grag et al. are expected to provide antimicrobial activities. Additionally, cleansing the skin with wipe or towelette will remove materials attached to the surface of the skin including dirt, secretion and microbes that cause vaginitis. Treating vaginitis is accompanied by removal of the cause of the bad odor, and no need to add fragrance. The prior art in combination teaches the present invention as a whole, and teach all the ingredients as instantly claimed, and same ingredients expected to have the same properties, such as odor control, since materials and their properties are inseparable. The ingredients disclosed by the reference as cleanser are expected to have anti-infective effect when applied to the vagina since materials and their properties are inseparable.

A conclusion of obviousness under 35 U.S.C. 103 (a) does not require absolute predictability, only a reasonable expectation of success; and references are evaluated by what they suggest to one versed in the art, rather than by their specific disclosure. *In re Bozek*, 163 USPQ 545 (CCPA 1969).

In the light of the foregoing discussion, the Examiner's ultimate legal conclusion is that the subject matter defined by the claims would have been *prima facie* obvious within the meaning of 35 U.S.C. 103 (a).

Conclusion

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Isis A. Ghali whose telephone number is (571) 272-0595. The examiner can normally be reached on Monday-Thursday, 6:30 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Sharmila Landau can be reached on (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Isis A Ghali/
Primary Examiner, Art Unit 1611

IG